Annual report pursuant to Section 13 and 15(d)

Consolidated and Combined Statements of Operations

v3.19.3.a.u2
Consolidated and Combined Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Operating expenses:    
Research and development $ 20,061 $ 35,583
General and administrative 27,012 29,453
Change in contingent consideration valuation (14,554) 8,499
Total operating expenses 32,519 73,535
Operating loss (32,519) (73,535)
Other income (expense):    
Other income (expense) (38) (132)
Net loss $ (32,557) $ (73,667)
Per share information:    
Net loss per share of common stock, basic and diluted $ (3.48) $ (7.88)
Weighted average common shares outstanding, basic and diluted 9,350,709 9,350,709